AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

PMGC Holdings Inc.

$4.52 -$1358.68 (-99.67%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$4.6
Day Range
$4.52$4.74
Year Range
$4.4$2671.2
Market Cap
2.05M
AVG Volume
221.64K
Trailing/Forward PE
-0/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
NASDAQUS
Revenue (USD)
-2M-1M01M2M2022202320242025
ELAB Revenue (USD) by year
PeriodRevenue (USD)
2025590.08K
2024-1.13M
20231.71M
2022766.28K
Net Income (USD)
-8M-6M-4M-2M02022202320242025
ELAB Net Income (USD) by year
PeriodNet Income (USD)
2025-7.75M
2024-6.25M
2023-4.3M
2022-1.8M
Operating Income (USD)
-8M-6M-4M-2M02022202320242025
ELAB Operating Income (USD) by year
PeriodOperating Income (USD)
2025-7.38M
2024-1.63M
2023-3.68M
2022-1.78M
EBITDA (USD)
-8M-6M-4M-2M02022202320242025
ELAB EBITDA (USD) by year
PeriodEBITDA (USD)
2025-7.44M
2024-3.2M
2023-4.27M
2022-1.77M
Cash Flows (USD)
-8M-6M-4M-2M02022202320242025
ELAB Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-6.38M
2024-5.96M
2023-4.57M
2022-1.62M
EPS (USD)
-30000-20000-1000002022202320242025
ELAB EPS (USD) by year
PeriodEPS (USD)
2025-4557.3
2024-29771.76
2023-7903.68
2022-11.39
Expenses (USD)
-2M02M4M6MR&DSG&ACapex2022202320242025
ELAB Expenses (USD) by year
PeriodExpenses (USD)
20252.21M
20242.7M
20234.47M
20222.03M
Cash & Debt (USD)
02M4M6MCashLong Term DebtShort Term Debt2022202320242025
ELAB Cash & Debt (USD) by year
PeriodCash & Debt (USD)
20255.4M
20243.98M
20233.33M
20221.15M
Debt ratios
00.511.52025
ELAB Debt ratios by year
PeriodDebt ratios
20250.17
Margins
0%50%100%150%200%2022202320242025
ELAB Margins by year
PeriodMargins
202512.68%
2024161.25%
202366.25%
202258.37%
Return on Capital
-200%-150%-100%-50%0%2022202320242025
ELAB Return on Capital by year
PeriodReturn on Capital
2025-98.86%
2024-93.79%
2023-112.4%
2022-159.13%
Shares Outstanding
050K100K150K2022202320242025
ELAB Shares Outstanding by year
PeriodShares Outstanding
20252.04K
2024601
2023147
2022113.91K
Book Value Per Share (USD)
01000020000300002022202320242025
ELAB Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20253851.28
202411080.81
202326034.53
20229.93
Total Assets (USD)
05M10M15M2022202320242025
ELAB Total Assets (USD) by year
PeriodTotal Assets (USD)
202512.87M
20248.99M
20235.19M
20221.89M
Employee Count
010203040202320242025
ELAB Employee Count by year
PeriodEmployee Count
202532
20242
202316
Free Cash Flow Yield
-20000%-15000%-10000%-5000%0%med -70.48%Aug 24Nov 24Feb 25Jun 25Sep 25Jan 26Apr 26
ELAB Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Apr 26-12583.28%
Apr 26-9552.55%
Apr 26-6541.21%
Apr 26-5477.69%
Mar 26-17893.43%
Mar 26-8489.21%
Mar 26-6524.46%
Mar 26-6730.19%
Feb 26-4185.16%
Feb 26-3860.73%
Feb 26-3635.28%
Feb 26-2829.74%
Jan 26-1418.9%
Jan 26-1418.9%
Jan 26-1566.14%
Jan 26-948.64%
Jan 26-219.2%
Dec 25-200.82%
Dec 25-137.73%
Dec 25-80.85%
Dec 25-62.76%
Nov 25-58.62%
Nov 25-65.95%
Nov 25-58.73%
Nov 25-70.28%
Oct 25-64.36%
Oct 25-63.18%
Oct 25-55.39%
Oct 25-69.77%
Oct 25-71.47%
Sep 25-70.67%
Sep 25-65.57%
Sep 25-79.84%
Sep 25-84.25%
Aug 25-67.31%
Aug 25-45.98%
Aug 25-56.45%
Aug 25-120.08%
Aug 25-115.68%
Jul 25-99.01%
Jul 25-95.65%
Jul 25-102.08%
Jul 25-100.78%
Jun 25-105.49%
Jun 25-109.58%
Jun 25-108.53%
Jun 25-103.96%
May 25-107.94%
May 25-96%
May 25-91.34%
May 25-123.98%
May 25-119.95%
Apr 25-130.56%
Apr 25-113.49%
Apr 25-96.07%
Apr 25-68.94%
Mar 25-60.82%
Mar 25-194.09%
Mar 25-228.98%
Mar 25-189.91%
Feb 25-109.84%
Feb 25-82.88%
Feb 25-80.43%
Feb 25-72.73%
Jan 25-79.95%
Jan 25-44.11%
Jan 25-64.19%
Jan 25-66.38%
Jan 25-55.13%
Dec 24-56.04%
Dec 24-53.41%
Dec 24-59.7%
Dec 24-67.03%
Nov 24-66.69%
Nov 24-34.01%
Nov 24-30.94%
Nov 24-44.19%
Nov 24-28.9%
Oct 24-8.24%
Oct 24-8.97%
Oct 24-8.91%
Oct 24-7.73%
Sep 24-9.05%
Sep 24-2.98%
Sep 24-2.39%
Sep 24-2.87%
Aug 24-3.14%
Aug 24-2.72%
Aug 24-2.81%
Aug 24-2.64%
Aug 24-2.23%
Jul 24-1.98%
Jul 24-1.75%
Jul 24-1.74%
Jul 24-1.52%
Jun 24-1.51%
Jun 24-1.51%
Jun 24-1.49%
Jun 24-1.38%
May 24-1.33%
Price to Sales
-1000100200300med -0.07Aug 24Nov 24Feb 25Jun 25Sep 25Jan 26Apr 26
ELAB Price to Sales by year
PeriodPrice to Sales
Apr 260.09
Apr 260.11
Apr 260.17
Apr 260.2
Mar 26-0.03
Mar 26-0.05
Mar 26-0.07
Mar 26-0.07
Feb 26-0.11
Feb 26-0.12
Feb 26-0.12
Feb 26-0.16
Jan 26-0.32
Jan 26-0.32
Jan 26-0.29
Jan 26-0.47
Jan 26-2.05
Dec 25-2.24
Dec 25-3.27
Dec 25-5.57
Dec 25-7.17
Nov 25-7.68
Nov 25-6.83
Nov 25-7.67
Nov 25-4.42
Oct 25-4.82
Oct 25-4.91
Oct 25-5.61
Oct 25-4.45
Oct 25-4.34
Sep 25-4.39
Sep 25-4.73
Sep 25-3.89
Sep 25-3.69
Aug 25-4.61
Aug 25-6.75
Aug 25-5.5
Aug 25-2.35
Aug 25-2.44
Jul 25-2.85
Jul 25-2.94
Jul 25-2.76
Jul 25-2.8
Jun 25-2.67
Jun 25-2.57
Jun 25-2.6
Jun 25-2.71
May 25-2.61
May 25-2.93
May 25-3.08
May 25-4.24
May 25-4.38
Apr 25-4.03
Apr 25-4.63
Apr 25-5.47
Apr 25-7.63
Mar 25-8.65
Mar 252.37
Mar 252.01
Mar 252.42
Feb 254.19
Feb 255.56
Feb 255.72
Feb 256.33
Jan 255.76
Jan 2510.44
Jan 257.17
Jan 256.94
Jan 258.35
Dec 248.22
Dec 248.62
Dec 247.71
Dec 246.87
Nov 246.9
Nov 2413.54
Nov 2414.88
Nov 247.43
Nov 2411.35
Oct 2439.8
Oct 2436.58
Oct 2436.81
Oct 2442.43
Sep 2436.26
Sep 24110.01
Sep 24137.51
Sep 24114.41
Aug 24104.66
Aug 24120.61
Aug 24116.69
Aug 24104.82
Aug 24124.13
Jul 24140.08
Jul 24158.25
Jul 24159.68
Jul 24182.03
Jun 24183.61
Jun 24183.61
Jun 24186.27
Jun 24201.02
May 24208.93
Price to Book
010203040med 0.62Dec 24Mar 25Jul 25Oct 25Jan 26May 26Sep 26
ELAB Price to Book by year
PeriodPrice to Book
Sep 260.13
Sep 260.15
Aug 260.15
Aug 260.19
Aug 260.27
Aug 260.03
Jul 260.03
Jul 260.03
Jul 260.04
Jul 260.04
Jul 260.04
Jun 260.04
Jun 260.05
Jun 260.05
Jun 260.05
May 260.06
May 260.06
May 260.07
Apr 260.01
Apr 260.01
Apr 260.01
Apr 260.01
Mar 260
Mar 260.01
Mar 260.01
Mar 260.01
Feb 260.02
Feb 260.02
Feb 260.02
Feb 260.03
Jan 260.05
Jan 260.05
Jan 260.05
Jan 260.08
Jan 260.35
Dec 250.39
Dec 250.56
Dec 250.96
Dec 251.23
Nov 251.32
Nov 251.18
Nov 251.32
Nov 250.85
Oct 250.93
Oct 250.95
Oct 251.08
Oct 250.86
Oct 250.84
Sep 250.85
Sep 250.91
Sep 250.75
Sep 250.71
Aug 250.89
Aug 251.3
Aug 251.06
Aug 250.5
Aug 250.52
Jul 250.61
Jul 250.63
Jul 250.59
Jul 250.6
Jun 250.57
Jun 250.55
Jun 250.56
Jun 250.58
May 250.56
May 250.63
May 250.66
May 250.72
May 250.75
Apr 250.69
Apr 250.79
Apr 250.93
Apr 251.3
Mar 251.47
Mar 250.36
Mar 250.31
Mar 250.37
Feb 250.64
Feb 250.85
Feb 250.88
Feb 250.97
Jan 250.88
Jan 251.6
Jan 251.1
Jan 251.06
Jan 251.28
Dec 241.26
Dec 241.32
Dec 241.18
Dec 241.05
Nov 241.06
Nov 242.08
Nov 242.28
Nov 245.25
Nov 248.03
Oct 2428.16
Oct 2425.88
Oct 2426.05
Oct 2430.02
PMGC Holdings Inc.
ELAB
Stockpicker

Video analysis: ELAB

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ELAB

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

globenewswire.com · 1 Sep 2026

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio

globenewswire.com · 26 Aug 2026

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Acr

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

globenewswire.com · 25 Aug 2026

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

globenewswire.com · 21 Aug 2026

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

globenewswire.com · 19 Aug 2026

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

NEWPORT BEACH, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-10 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 12:00 am, Eastern time, on August 21, 2026.

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles Sequentially

globenewswire.com · 14 Aug 2026

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles Sequentially

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-o

PMGC Holdings Confirms Compliance with Nasdaq's New $5 Million Market Value of Listed Securities Requirement

globenewswire.com · 29 Jul 2026

PMGC Holdings Confirms Compliance with Nasdaq's New $5 Million Market Value of Listed Securities Requirement

Company Reports 8,095,835 Shares of Common Stock Issued and Outstanding as of July 29, 2026, and Moves to Correct Third-Party Market Data That Understates Its Current Share Count and Market Capitalization Company Reports 8,095,835 Shares of Common Stock Issued and Outstanding as of July 29, 2026, and Moves to Correct Third-Party Market Data That Understates Its Current Share Count and Market Capitalization

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

globenewswire.com · 28 Jul 2026

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

NEWPORT BEACH, Calif. , July 28, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the "Company," "PMGC," "we," or "our"), a diversified holding company executing a precision manufacturing growth strategy across the aerospace and defense supply chain, today announced that its wholly owned subsidiary, A&B Aerospace, Inc.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.